

# A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis

**Submission date**

19/09/2006

**Recruitment status**

No longer recruiting

**Registration date**

27/06/2007

**Overall study status**

Completed

**Last Edited**

15/03/2016

**Condition category**

Nutritional, Metabolic, Endocrine

☐ Prospectively registered

☐ Protocol

☐ Statistical analysis plan

☐ Results

☐ Individual participant data

☐ Record updated in last year

**Plain English summary of protocol**

Not provided at time of registration

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Neil Wright

**Contact details**

Sheffield Children's NHS Foundation Trust

Academic Unit of Child Health

C Floor Stephenson Wing

Western Bank

Sheffield

United Kingdom

S10 2TH

## Additional identifiers

**Protocol serial number**

SCH-05-015

## Study information

**Scientific Title**

A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis

**Study objectives**

To establish a better methodology for identifying patients with Cystic Fibrosis Related Diabetes mellitus (CFRD) and to show that early treatment produces clinical benefits.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

West Midlands Research Ethics Committee, 17/10/2005

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Cystic Fibrosis Related Diabetes mellitus (CFRD)

**Interventions**

Children will be randomised to receive Insulin detemir 0.2 units per kg body weight by once daily subcutaneous injection daily for one year. The control group will receive no intervention. There is no placebo or sham treatment (it was not felt appropriate given that it would require a daily injection).

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Insulin detemir

**Primary outcome(s)**

Measurements of beta-cell function

**Key secondary outcome(s))**

1. Height, weight, Body Mass Index (BMI), triceps and biceps skin fold thickness
2. Respiratory function testing
3. Three monthly glycosylated haemoglobin
4. Adverse event monitoring

**Completion date**

01/11/2009

**Eligibility**

**Key inclusion criteria**

Any child over ten years of age with either fasting plasma glucose more than 6.1 mmol/l but less than 7.0 mmol/l and/or a two hour glucose of more than 7.8 mmol/l but less than 11.1 mmol/l.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

10 years

**Sex**

All

**Key exclusion criteria**

1. Failure to provide informed consent
2. Pre-existing insulin or oral hypoglycaemic agent treatment

**Date of first enrolment**

01/10/2006

**Date of final enrolment**

01/11/2009

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Sheffield Children's NHS Foundation Trust

Sheffield

United Kingdom

S10 2TH

**Sponsor information**

**Organisation**

Sheffield Children's NHS Foundation Trust (UK)

**ROR**

<https://ror.org/02md8hv62>

**Funder(s)****Funder type**

Charity

**Funder Name**

British Society of Paediatric Endocrinology and Diabetes (UK) - Initial funding of £10,000 in November 2004

**Funder Name**

Sheffield Children's Appeal Charity (UK) - £32,000 in early 2005

**Funder Name**

Novo Nordisk (UK) - the makers of Detemir; £72,000 (post MREC approval) in summer 2005

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration